Content area

|
|

Vaccination til forebyggelse af meningokoksygdom

Forfatter(e)
Nanna Himmelstrup1, Cecilie Helkjær Engen1, Lars Østergaard2 & Thomas Lars Benfield1, 3 1) Infektionsmedicinsk Afdeling, Amager og Hvidovre Hospital2) Infektionsmedicinsk Afdeling, Aarhus Universitetshospital3) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2019;181:V09180611
Reference: 
Ugeskr Læger 2019;181:V09180611
Blad nummer: 

Nanna Himmelstrup, Cecilie Helkjær Engen, Lars Østergaard & Thomas Lars Benfield:

Vaccination for meningococcal disease

Ugeskr Læger 2019;181:V09180611

Neisseria meningiditis is a cause of sepsis and meningitis. Based on the capsule, six groups are recognised to cause invasive disease: A, B, C, W135, X and Y. In Denmark, five vaccines are marketed to protect against five of the six groups. One conjugated glycoprotein vaccine against serogroup C alone: MenC, two conjugated vaccines against ACWY: ACWY-TT/ACWY-CRM, and two protein-based vaccines against serogroup B: 4CMenB and MenB-fHbp. Overall, the efficacy is good, but the persistence of immunity is decreasing over time, why a booster is recommended for long-term protection.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Langhoff-Roos | 17/10
3 kommentarer
af Tomas Christensen Kjær | 16/10
1 Kommentar
af Lars Lindberg Andersen | 15/10
1 Kommentar
af Johan Tommy Robert Wallentin | 14/10
1 Kommentar
af Kristian Valbak | 11/10
2 kommentarer
af Birger Kreutzfeldt | 11/10
1 Kommentar
af Bodil | 11/10
5 kommentarer